Trials / Completed
CompletedNCT00210327
VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy
Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-cell Lymphoma of MALT-type Pretreated With Prior Systemic Therapy Regimen (X05142)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (estimated)
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG) · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the antitumor activity (in terms of overall response rate - ORR - i.e. sum of complete and partial responses)of bortezomib in pretreated MALT lymphomas with one prior sistemic therapy regimen
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bortezomib (drug) |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2008-11-01
- Completion
- 2009-04-01
- First posted
- 2005-09-21
- Last updated
- 2009-07-22
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00210327. Inclusion in this directory is not an endorsement.